Today: Girls and Reality TV, Stars' Awkward Photos, Hollywood Cradle Robbers
Sorted by: Top Picks

How many people have gotten HIV/Hep C from blood transfusion since testing began?

By forestdeloachzhang on  From gooanemia.info
by Lighthouse50 How many people have gotten HIV/Hep C from blood transfusion since testing began ? I’m not sure about the number, but the chance is less than 1 case per million transfusions. tried nejm.com? pubmed? who.org cdc.gov might also helpThere hasn’t been a documented cases of transmission via the blood supply since testing began in about 1985/6 for HIV (at least in Canada, not sure about the US). The risk is very low now: HIV – about 1 in 1.6 million with current testing...Read Full Story

BioLineRx In-Licenses Second Oral Hepatitis C Treatment

By stoktwit on  From crwepicks.com
Worldwide, exclusive deal signed with Genoscience and RFS Pharma for development and commercialization of BL-8030 Advantages of BL-8030 include high specificity, improved resistance profile, reduced toxicity and potentially reduced drug-drug interactions JERUSALEM — (CRWENEWSWIRE) — BioLineRx (NASDAQ:BLRX) (TASE:BLRX), a biopharmaceutical development company, announced today it has signed a worldwide, exclusive license agreement with Genoscience and RFS Pharma to develop and commercialize...Read Full Story

BioLineRx In-Licenses Second Oral Hepatitis C Treatment

By StockTips1 on  From stockhottips.com
Worldwide, exclusive deal signed with Genoscience and RFS Pharma for development and commercialization of BL-8030 Advantages of BL-8030 include high specificity, improved resistance profile, reduced toxicity and potentially reduced drug-drug interactions JERUSALEM — (CRWENEWSWIRE) — BioLineRx (NASDAQ:BLRX) (TASE:BLRX), a biopharmaceutical development company, announced today it has signed a worldwide, exclusive license agreement with Genoscience and RFS Pharma to develop and commercialize...Read Full Story

BioLineRx In-Licenses Second Oral Hepatitis C Treatment

By karmastock on  From pennyomega.com
Worldwide, exclusive deal signed with Genoscience and RFS Pharma for development and commercialization of BL-8030 Advantages of BL-8030 include high specificity, improved resistance profile, reduced toxicity and potentially reduced drug-drug interactions JERUSALEM — (CRWENEWSWIRE) — BioLineRx (NASDAQ:BLRX) (TASE:BLRX), a biopharmaceutical development company, announced today it has signed a worldwide, exclusive license agreement with Genoscience and RFS Pharma to develop and commercialize...Read Full Story

BioLineRx In-Licenses Second Oral Hepatitis C Treatment

By karmastock on  From doubleinstocks.com
Worldwide, exclusive deal signed with Genoscience and RFS Pharma for development and commercialization of BL-8030 Advantages of BL-8030 include high specificity, improved resistance profile, reduced toxicity and potentially reduced drug-drug interactions JERUSALEM — (CRWENEWSWIRE) — BioLineRx (NASDAQ:BLRX) (TASE:BLRX), a biopharmaceutical development company, announced today it has signed a worldwide, exclusive license agreement with Genoscience and RFS Pharma to develop and commercialize...Read Full Story
Sorted by: Top Rated
No pictures yet.
NEW YORK (TheStreet) -- Why is everyone obsessed with hepatitis C? Initially described as "non-A/non-B," hepatitis C (HCV) didn't even have a proper name until the late 1980s, much less the rabid following the viral liver disease now enjoys in ...  
From api.bing.com ()
Related news:
More perspectives...
Chronic hepatitis B virus (HBV) infection is a leading cause of cirrhosis and liver cancer worldwide; [1] the estimated prevalence in the United States is 0.3%–0.5%. [2] Each year, approximately 11,500–13,000 persons are newly reported with ...  
From api.bing.com ()
Related news:
More perspectives...
The U.S. Food and Drug Administration said Thursday the use of Merck & Co.'s (MRK) Hepatitis C drug Victrelis with certain types of HIV medicines may reduce effectiveness of both types of treatments. Victrelis was approved last year to treat Hepatitis C, a liver disease caused by infection with the hepatitis C virus, which is transmitted through contaminated blood. Although Victrelis wasn't approved...  
From rss.biospace.com ()
Related news:
More perspectives...
Combination therapy with pegylated interferon (PEG-IFN) and ribavirin long stood as the standard of care for chronic hepatitis C virus (HCV) infection. Although effective in achieving high rates of sustained virologic response (SVR), this ...  
From api.bing.com ()
More perspectives...
SAN DIEGO - February 7, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that a presentation of the Aethlon Hemopurifier to treat Hepatitis C virus (HCV) and other infectious disease conditions will occur at the upcoming 32nd Annual Dialysis Conference to be held...  
From investorideas.com ()
Related news:
More perspectives...
More From Zimbio
Zimbio Entertainment
Copyright © 2012 - Zimbio, Inc. Some rights reserved.
Share
. . .
Follow
. . .